pharma
J&J’s ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis
July 26, 2019Medical Communications, Research and Development Johnson & Johnson, multiple sclerosis, pharma, ponesimod
New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …
AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers
July 26, 2019Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma
NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …
BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer
July 25, 2019Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …
MRI scans can help predict MS patient’s long term prognosis, 15 year study shows
July 25, 2019Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma
MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …
Researchers design automatic opioid overdose antidote device
July 25, 2019Research and Development naloxone, opioid crisis, opioids, pharma, purdue university
Researchers at Purdue University are developing a device that would automatically detect an overdose in opioid users and release a …
Lilly’s Baqsimi nasal powder gains FDA approval after proving non-inferior to injection
July 25, 2019Sales and Marketing Baqsimi, Eli Lilly, FDA, US, diabetes, pharma
Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, …
Elizabeth Warren calls on Albert Bourla to reveal detail of appointment of former FDA commissioner Scott Gottlieb to Pfizer’s board
July 25, 2019Business Services, Medical Communications Albert Bourla, Elizabeth Warren, FDA, Pfizer, Scott Gottlieb, pharma
Elizabeth Warren has called on Pfizer to reveal the details of Scott Gottlieb’s appointment to the company’s Board of Directors.
Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US
July 24, 2019Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma
It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …
Senate puts forward bipartisan bill to lower price of drugs
July 24, 2019Research and Development PBMs, Senate, USA, access, bipartisan, pharma, pricing
The Senate Finance Committee has introduced a bipartisan bill that aimed at lowering the prices Medicare pays for pharmaceutical drugs. …
FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan
July 24, 2019Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma
Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …
MSD trials long lasting PrEP implant for preventing HIV
July 23, 2019Research and Development AIDS, HIV, MSD, PrEP, pharma
MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …
Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease
July 23, 2019Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …
FDA approves nine generic versions of Pfizer’s Lyrica
July 23, 2019Manufacturing and Production, Sales and Marketing FDA, Lyrica, Pfizer, pharma
The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the …
Acadia’s schizophrenia drug flops in Phase 3 trial
July 23, 2019Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia
Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …
FDA knocks back Biohaven’s ALS drug over manufacturing concerns
July 22, 2019Sales and Marketing Biohaven, FDA, Nurtec, amyotrophic lateral sclerosis, pharma
Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
